Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
Clinical trial NCT03787095 · TERMINATED
Trial details
- NCT number
- NCT03787095
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-13
- Primary completion
- 2020-08-18
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.